“…However, this was given as long-term therapy and predates the modern AS era, in which the clinically important endpoint is not survival but avoiding active treatment for disease progression [1,2,5]. Interest in this area has now re-emerged with a better understanding of disease prognosis, the acceptance of AS for mainstream management, and better selective ATT drugs [19]. The ENACT study, for example, has treated men on AS with enzalutamide (NCT02799745) or placebo.…”